We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Logo

Evotec

Evotec are a R&D biotech that offers accelerating, high value pipeline co-creation partnerships and comprehensive CRO/CDMO services – always striving for highest quality, capital efficient execution of R&D programs from disease understanding towards IND, Phase 1, and beyond. Our expertise spans across therapeutic/disease areas and most modalities, especially small molecules and biotherapeutics. We take pride in acting as "drug hunters" in deep collaboration with our partners to advance science. At the core of our operations are our industrialized, AI-powered proprietary R&D platforms, including PanOmics and iPSC technologies. These platforms are instrumental in enhancing disease understanding and ensuring human relevance in our research. By integrating AI and continuous manufacturing technology, we facilitate better access to high-quality biotherapeutics, revolutionizing the way treatments are developed and produced.

Latest Content

A purple brain.
Product News

Evotec Announces Key Progress in Neuroscience Collaboration With Bristol Myers Squibb

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY).
Scientist wearing a lab coat, hairnet, face mask and gloves working in a bioprocessing facility.
Article

The Promise of Continuous Processing To Advance Biopharmaceutical Production

This article explores how switching to an automated continuous manufacturing process can improve product yields and quality, lower capital expenditures, reduce facility footprints and minimize waste, ultimately reducing the price tag of biologics.
Innovations in Biopharma 2025
Online Event

Innovations in Biopharma 2025

New for 2025, this event will provide insights from both big pharma and emerging biotech firms. Attendees will gain a comprehensive understanding of how rapid technological advancements are reshaping therapeutic development and delivery.
Antibodies.
Product News

Evotec Receives Grant From Korean Government To Develop Novel Antibody-Based Treatments for Lung Diseases

Evotec SE announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT).
Three researchers in a lab.
Product News

Evotec SE Announces First Projects for LAB eN² Drug Discovery Accelerator With Novo Nordisk

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases.
A snippet of spatial transcriptomics in neuroscience infographic on a dark navy background.
Infographic

Spatial Transcriptomics in Neuroscience

Single-cell RNA sequencing (scRNA-seq) approaches can provide transcriptomic profiles of individual cells isolated from brain tissue.
Transparent molecular structure representation illustrating concepts in harnessing structural insights for drug discovery.
Webinar

Harnessing Structural Insights in Drug Discovery

On-Demand
This webinar explores how structural biology drives success in drug discovery projects.
Digital rendering of a DNA helix and a medication bottle symbolizing therapeutic siRNA applications
Webinar

Therapeutic siRNAs: Considerations for “Picking the Best One”

On-Demand
Explore strategies to optimize siRNA drug development, including sequence selection, molecular design, IP, manufacturing, machine learning for mRNA target optimization, and medicinal chemistry to refine candidates for clinical success.
Blue drug capsule filled with small spheres, set against a background of target neural cells.
Article

Trends in Target-Based Drug Discovery

In this article, we highlight how target discovery has advanced and explore the growing role that computational approaches are playing in modern drug target identification.
Cells.
Product News

Evotec and Bristol Myers Squibb Expand Proteomics Partnership

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
Advertisement